(Q42772433)

English

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial

scientific article published on January 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

1 reference

based on heuristic

inferred from title

author name string

Anita Brogan

1

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Josephine Mauskopf

2

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Sandra E Talbird

3

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Erik Smets

4

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

28 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

129-146

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Estimating the proportion of patients infected with HIV who will die of comorbid diseases

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

The survival benefits of AIDS treatment in the United States

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

The CD4 lymphocyte count and risk of clinical progression

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study.

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Longevity and health care expenditures: the real reasons older people spend more

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Productivity costs and determinants of productivity in HIV-infected patients

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Management of protease inhibitor-associated diarrhea

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Benefits and concerns of simplification strategies in HIV-infected patients

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy

2 references

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

Modeling the Long-Term Outcomes and Costs of HIV Antiretroviral Therapy Using HIV RNA Levels: Application to a Clinical Trial

1 reference

https://api.crossref.org/works/10.2165%2F11587490-000000000-00000

21 January 2018

A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Approach to the treatment-experienced patient

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunopathogenesis of human immunodeficiency virus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic costs of HIV infection: an employer's perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HIV Drug Resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21182348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11587490-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42772433&oldid=2205644007"